Anti-IL-5 and anti-IL-5 receptor therapy significantly improves quality of life and FEV1 values in patients with severe asthma
Abstract In recent years, the use of monoclonal antibodies directed against interleukin-5 (anti-IL-5) and its receptor alpha (anti-IL-5R) has proven to be an effective therapeutic option for patients with severe asthma by reducing the number of eosinophils, which may promote disease remission. This...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-08-01
|
| Series: | Allergy, Asthma & Clinical Immunology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13223-025-00979-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849235014168870912 |
|---|---|
| author | Anaiza Odalis Villalobos Alfaro Haydee Carolina Gutiérrez Vargas Juan Manuel Díaz Jonathan Alvarez Pinto Diana Cristina García Cambero Eduardo Hernandez Cuellar Julio Augusto Palma Zapata Alondra Esthefanía Llamas Domínguez Juliana Palma Zapata Silvia Denise Ponce-Campos |
| author_facet | Anaiza Odalis Villalobos Alfaro Haydee Carolina Gutiérrez Vargas Juan Manuel Díaz Jonathan Alvarez Pinto Diana Cristina García Cambero Eduardo Hernandez Cuellar Julio Augusto Palma Zapata Alondra Esthefanía Llamas Domínguez Juliana Palma Zapata Silvia Denise Ponce-Campos |
| author_sort | Anaiza Odalis Villalobos Alfaro |
| collection | DOAJ |
| description | Abstract In recent years, the use of monoclonal antibodies directed against interleukin-5 (anti-IL-5) and its receptor alpha (anti-IL-5R) has proven to be an effective therapeutic option for patients with severe asthma by reducing the number of eosinophils, which may promote disease remission. This study aimed to evaluate clinical improvement and remission in patients with severe asthma treated with anti-IL-5 and anti-IL-5R antibodies over a period of 12 months. A cohort study was conducted with 49 patients diagnosed with severe eosinophilic asthma and who did not respond to conventional treatment. During follow-up, medical control was performed every 3 months using spirometry, eosinophil counts, quality of life scales, and disease control. The results revealed an improvement in FEV1 after 3 months of treatment, with statistical significance at 12 months in patients treated with anti-IL-5 and at 9 months in those treated with anti-IL-5R. In addition, better perceptions of asthma control and quality of life were observed, with significant differences at 6 and 12 months. Correlations between spirometry and ACT, ACQ, and AQLQ reflect a progressive recovery of well-being and function. Finally, the remission rate was 41.1% with anti-IL-5 treatment and 47.3% with anti-IL-5R treatment after one year of follow-up. These findings support the efficacy of anti-IL-5 and anti-IL-5R treatment in improving severe asthma control and patients’ quality of life, suggesting their key role in disease remission. |
| format | Article |
| id | doaj-art-7197231ae32544f3ad3c54fa154da8d3 |
| institution | Kabale University |
| issn | 1710-1492 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | BMC |
| record_format | Article |
| series | Allergy, Asthma & Clinical Immunology |
| spelling | doaj-art-7197231ae32544f3ad3c54fa154da8d32025-08-20T04:02:56ZengBMCAllergy, Asthma & Clinical Immunology1710-14922025-08-0121111310.1186/s13223-025-00979-yAnti-IL-5 and anti-IL-5 receptor therapy significantly improves quality of life and FEV1 values in patients with severe asthmaAnaiza Odalis Villalobos Alfaro0Haydee Carolina Gutiérrez Vargas1Juan Manuel Díaz2Jonathan Alvarez Pinto3Diana Cristina García Cambero4Eduardo Hernandez Cuellar5Julio Augusto Palma Zapata6Alondra Esthefanía Llamas Domínguez7Juliana Palma Zapata8Silvia Denise Ponce-Campos9Department of Medicine, Cuauhtémoc UniversityInstitute of Security and Social Services for State WorkersDepartment of Microbiology and Immunology, University of Western OntarioInstitute of Security and Social Services for State WorkersMexican Social Security InstituteDepartment of Morphology, Autonomous University of AguascalientesDepartment of Medicine, Autonomous University of AguascalientesDepartment of Medicine, Autonomous University of AguascalientesDepartment of Medicine, Autonomous University of AguascalientesInstitute of Security and Social Services for State WorkersAbstract In recent years, the use of monoclonal antibodies directed against interleukin-5 (anti-IL-5) and its receptor alpha (anti-IL-5R) has proven to be an effective therapeutic option for patients with severe asthma by reducing the number of eosinophils, which may promote disease remission. This study aimed to evaluate clinical improvement and remission in patients with severe asthma treated with anti-IL-5 and anti-IL-5R antibodies over a period of 12 months. A cohort study was conducted with 49 patients diagnosed with severe eosinophilic asthma and who did not respond to conventional treatment. During follow-up, medical control was performed every 3 months using spirometry, eosinophil counts, quality of life scales, and disease control. The results revealed an improvement in FEV1 after 3 months of treatment, with statistical significance at 12 months in patients treated with anti-IL-5 and at 9 months in those treated with anti-IL-5R. In addition, better perceptions of asthma control and quality of life were observed, with significant differences at 6 and 12 months. Correlations between spirometry and ACT, ACQ, and AQLQ reflect a progressive recovery of well-being and function. Finally, the remission rate was 41.1% with anti-IL-5 treatment and 47.3% with anti-IL-5R treatment after one year of follow-up. These findings support the efficacy of anti-IL-5 and anti-IL-5R treatment in improving severe asthma control and patients’ quality of life, suggesting their key role in disease remission.https://doi.org/10.1186/s13223-025-00979-yAsthmaAnti-IL-5Anti-IL5RACQ5 |
| spellingShingle | Anaiza Odalis Villalobos Alfaro Haydee Carolina Gutiérrez Vargas Juan Manuel Díaz Jonathan Alvarez Pinto Diana Cristina García Cambero Eduardo Hernandez Cuellar Julio Augusto Palma Zapata Alondra Esthefanía Llamas Domínguez Juliana Palma Zapata Silvia Denise Ponce-Campos Anti-IL-5 and anti-IL-5 receptor therapy significantly improves quality of life and FEV1 values in patients with severe asthma Allergy, Asthma & Clinical Immunology Asthma Anti-IL-5 Anti-IL5R ACQ5 |
| title | Anti-IL-5 and anti-IL-5 receptor therapy significantly improves quality of life and FEV1 values in patients with severe asthma |
| title_full | Anti-IL-5 and anti-IL-5 receptor therapy significantly improves quality of life and FEV1 values in patients with severe asthma |
| title_fullStr | Anti-IL-5 and anti-IL-5 receptor therapy significantly improves quality of life and FEV1 values in patients with severe asthma |
| title_full_unstemmed | Anti-IL-5 and anti-IL-5 receptor therapy significantly improves quality of life and FEV1 values in patients with severe asthma |
| title_short | Anti-IL-5 and anti-IL-5 receptor therapy significantly improves quality of life and FEV1 values in patients with severe asthma |
| title_sort | anti il 5 and anti il 5 receptor therapy significantly improves quality of life and fev1 values in patients with severe asthma |
| topic | Asthma Anti-IL-5 Anti-IL5R ACQ5 |
| url | https://doi.org/10.1186/s13223-025-00979-y |
| work_keys_str_mv | AT anaizaodalisvillalobosalfaro antiil5andantiil5receptortherapysignificantlyimprovesqualityoflifeandfev1valuesinpatientswithsevereasthma AT haydeecarolinagutierrezvargas antiil5andantiil5receptortherapysignificantlyimprovesqualityoflifeandfev1valuesinpatientswithsevereasthma AT juanmanueldiaz antiil5andantiil5receptortherapysignificantlyimprovesqualityoflifeandfev1valuesinpatientswithsevereasthma AT jonathanalvarezpinto antiil5andantiil5receptortherapysignificantlyimprovesqualityoflifeandfev1valuesinpatientswithsevereasthma AT dianacristinagarciacambero antiil5andantiil5receptortherapysignificantlyimprovesqualityoflifeandfev1valuesinpatientswithsevereasthma AT eduardohernandezcuellar antiil5andantiil5receptortherapysignificantlyimprovesqualityoflifeandfev1valuesinpatientswithsevereasthma AT julioaugustopalmazapata antiil5andantiil5receptortherapysignificantlyimprovesqualityoflifeandfev1valuesinpatientswithsevereasthma AT alondraesthefaniallamasdominguez antiil5andantiil5receptortherapysignificantlyimprovesqualityoflifeandfev1valuesinpatientswithsevereasthma AT julianapalmazapata antiil5andantiil5receptortherapysignificantlyimprovesqualityoflifeandfev1valuesinpatientswithsevereasthma AT silviadeniseponcecampos antiil5andantiil5receptortherapysignificantlyimprovesqualityoflifeandfev1valuesinpatientswithsevereasthma |